EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IGF2BP2 binding to CPSF6 facilitates m6A‐mediated alternative polyadenylation of PUM2 and promotes malignant progression in ovarian cancer

Xin Luo iD, Qinglv Wei, Lingcui Xie, Ningxuan Chen, Bin Gu, Jiani Xu, Xiaoyan Jiang, Xinzhao Zuo, Hongyan Zhao, Xiaoyi Liu, Yu Yang, Tao Liu und 3 weitere

Clinical and Translational Medicine · 2025

DOI: 10.1002/ctm2.70388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Xin Luo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, RNA-Binding Proteins, Polyadenylation, Adenosine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chongqing Graduate Research Innovation Project, Third Affiliated Hospital of Chongqing Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

N6‐methyladenosine (m6A) and alternative polyadenylation (APA) are common posttranscriptional regulatory mechanisms in eukaryotes. However, the m6A‐dependent mechanism of APA regulation in ovarian cancer (OC) is still unclear.

Methods

The correlation between m6A and APA was analyzed by using RNA methylation sequencing of OC cells and single‐cell sequencing of clinical samples from public databases. To explore the core regulatory factors that served as a bridge between m6A and APA, we employed RNA pull‐down with biotin‐labelled m6A, immunoprecipitation, mass spectrometry, western blot, protein purification and GST pull‐down assays. Furthermore, the important target genes were screened by PAS‐seq, eCLIP‐seq, RIP‐seq and meRIP‐seq, and verified by RT‐qPCR, 3′RACE, RNA stability, and dual luciferase reporter assays. Multiple phenotypic experiments were conducted to evaluate the function of the IGF2BP2‐PUM2 axis in vitro and in vivo.

Results

This study found that the m6A was correlated with the APA and affected the 3′end processing in OC. The APA regulator CPSF6 tended to bind the m6A‐modified transcripts in OC cells. Mechanistically, we demonstrated that the m6A reader IGF2BP2 KH1‐4 domains could directly bind to the CPSF6‐RS domain to regulate the 3′end processing of OC. Furthermore, sequencing revealed that the m6A was highly enriched in the 3′UTR near the proximal polyadenylation signal (PAS), which promotes the use of proximal PAS and leads to 3′UTR shortening. PUM2 was carried m6A and recognized by IGF2BP2, and CPSF6 was recruited at the proximal polyadenylation signal (pPAS) to generate the short‐3′UTR transcript. The short PUM2 transcript was more stable than the long transcript, which promoted the malignant progression of OC.

Conclusions

We revealed a novel mechanism in which the m6A could regulate the APA processing of pre‐mRNAs by crosstalk of IGF2BP2 and CPSF6. This study provides a potential strategy for the effective treatment of OC. Highlights The interaction between m6A and APA is mediated by the m6A regulator IGF2BP2 and the APA factor CPSF6. The transcripts harboring m6A modification tend to use the proximal polyadenylation signal (PAS) in ovarian cancer (OC). PUM2 promotes the malignant progression of OC through its m6A methylation and APA processing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsRNA-Binding ProteinsPolyadenylationAdenosinemRNA Cleavage and Polyadenylation FactorsCleavage And Polyadenylation Specificity FactorHumansFemaleDisease ProgressionCell Line, TumorMiceAnimalsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

CPSF6IGF2BP2N6‐methyladenosinePUM2alternative polyadenylationovarian cancer

Substanzen

RNA-Binding ProteinsIGF2BP2 protein, humanAdenosinePUM2 protein, humanmRNA Cleavage and Polyadenylation FactorsN-methyladenosineCleavage And Polyadenylation Specificity Factor

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
  • Chongqing Municipal Health Commission Key Laboratory of Basic and Clinical Transformation of Gynecological Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
  • Chongqing Key Laboratory of Child Infection and Immunity, Children's Hospital of Chongqing Medical University, Chongqing, P.R. China.
  • School of Basic Medicine, Chongqing Medical University, Chongqing, P.R. China.
  • School of Basic Medicine, Hubei University of Medicine, Shiyan, P.R. China.

ORCID-Profile: Xin Luo, Ping Yi

Förderung

  • National Natural Science Foundation of China
  • Chongqing Graduate Research Innovation Project
  • Third Affiliated Hospital of Chongqing Medical University
  • CQMU Program for Youth Innovation in Future Medicine
  • Program for Key Disciplines Construction from Third Affiliated Hospital of Chongqing Medical University

Zitieren

APA

Luo, X., Wei, Q., Xie, L., Chen, N., Gu, B., Xu, J., Jiang, X., Zuo, X., Zhao, H., Liu, X., Yang, Y., Liu, T., Zhu, Y., Yi, P., & Xu, J. (2025). IGF2BP2 binding to CPSF6 facilitates m6A‐mediated alternative polyadenylation of PUM2 and promotes malignant progression in ovarian cancer. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70388

Vancouver

Luo X, Wei Q, Xie L, Chen N, Gu B, Xu J, et al. IGF2BP2 binding to CPSF6 facilitates m6A‐mediated alternative polyadenylation of PUM2 and promotes malignant progression in ovarian cancer. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70388

BibTeX
@article{Luo2025,
  author = {Luo, Xin and Wei, Qinglv and Xie, Lingcui and Chen, Ningxuan and Gu, Bin and Xu, Jiani and Jiang, Xiaoyan and Zuo, Xinzhao and Zhao, Hongyan and Liu, Xiaoyi and Yang, Yu and Liu, Tao and Zhu, Yong and Yi, Ping and Xu, Jing},
  title = {IGF2BP2 binding to CPSF6 facilitates m6A‐mediated alternative polyadenylation of PUM2 and promotes malignant progression in ovarian cancer},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  doi = {10.1002/ctm2.70388}
}
Kostenlos starten →